

## Nanexa named as finalist in Fierce Innovation Awards Life Sciences Edition 2025

**Nanexa, is pleased to announce that the company has been selected as a finalist in the Drug Delivery Technology category by the renowned industry publication Fierce Life Sciences. The annual *Fierce Life Sciences Innovation Awards* identify and showcase outstanding innovation that is driving improvements in life science technologies. Their panel of expert judges has identified Nanexa as a company whose pioneering solutions have the potential to create efficiencies, engage patients, or revolutionize the pharmaceutical industry.**

David Westberg, CEO of Nanexa, commented: "The entire Nanexa team is delighted that the potential of our technology has been acknowledged by Fierce Life Sciences. The PharmaShell platform is a truly ground-breaking technology for pharmaceutical formulation utilising atomic layer deposition (ALD) technology to encapsulate particles of active pharmaceutical ingredients (APIs) within an extremely thin shell, enabling extended and controlled release over months with unmatched precision. This will help to treat a broad range of chronic conditions and make a significant difference to the lives of millions of patients around the world, many of whom find it challenging to comply with daily dosing regimens."

PharmaShell has demonstrated suitability for long-acting controlled release of various APIs, including biologics and has recently provided clinical proof-of-concept of a monthly GLP-1 formulation. PharmaShell formulations could enable treatment of a variety of conditions, such as type 2 diabetes, obesity, cancers, cardiovascular diseases, and psychiatric disorders with just one injection per month or even less frequently.

**For additional information, please contact:**

---

David Westberg – CEO, Nanexa AB (publ)  
Phone: +46 70 942 83 03  
Email: [david.westberg@nanexa.se](mailto:david.westberg@nanexa.se)  
[www.nanexa.com](http://www.nanexa.com)

The company's Certified Adviser is Tapper Partners AB.

## About Nanexa AB (publ)

---

Nanexa is bringing the control, precision and versatility of Atomic Layer Deposition (ALD) technology to drug formulation. The company's proprietary PharmaShell® platform is a unique drug delivery system that enables a high drug load, thus low injection volume, creating a new generation of 'super generic' formulations that will provide greater convenience and reduce costs in the treatment of conditions such as metabolic diseases like type 2 diabetes and obesity, hematology/oncology, cardiovascular disorders, psychiatry, and many others. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others Novo Nordisk and AstraZeneca.

Nanexa's share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

## Attachments

---

[Nanexa named as finalist in Fierce Innovation Awards Life Sciences Edition 2025](#)